Hematology
Volume 24, 2019 - Issue 1
Articles
Re-personalization and stratification of hemophilia care in an evolving treatment landscape
Daniel P. HartThe Royal London Hospital Haemophilia Centre, Barts and The London School of Medicine, QMUL, London, UKCorrespondence[email protected]
https://orcid.org/0000-0001-9084-8598
https://orcid.org/0000-0001-9084-8598, & 
Related Research Data
Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients
Source:
American Society of Hematology
Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens
Source:
Georg Thieme Verlag KG
Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B.
Source:
Medical Journals Sweden AB
Intracranial haemorrhage in children with inherited bleeding disorders in the UK 2003-2015: A national cohort study
Source:
Wiley
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A
Source:
Massachusetts Medical Society
Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)
Source:
Wiley-Blackwell
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
Source:
American Society of Hematology
Haemophilia A: mutation type determines risk of inhibitor formation.
Source:
Georg Thieme Verlag KG
Novel therapeutics for hemophilia and other bleeding disorders
Source:
American Society of Hematology
Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A
Source:
Wiley
A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management
Source:
Wiley-Blackwell
Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial
Source:
Wiley-Blackwell
Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A
Source:
American Society of Hematology
Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors
Source:
New England Journal of Medicine (NEJM/MMS)
Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH
Source:
Wiley
Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A
Source:
American Society of Hematology
The principal results of the International Immune Tolerance Study: a randomized dose comparison
Source:
American Society of Hematology
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
Source:
Massachusetts Medical Society
Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)
Source:
Wiley
PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A
Source:
Wiley
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Source:
New England Journal of Medicine (NEJM/MMS)
The evolution of comprehensive haemophilia care in the United States: perspectives from the frontline.
Source:
Wiley
Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy
Source:
Massachusetts Medical Society
Linking provided by
